Skip to main content
. Author manuscript; available in PMC: 2020 May 11.
Published in final edited form as: Clin Ther. 2019 Jul 27;41(9):1681–1689. doi: 10.1016/j.clinthera.2019.07.003

Table II.

Infant outcomes. Values are given as mean (SD) unless otherwise indicated.

Variable Buprenorphine (n = 13) Naltrexone (n = 6) MD (95% CI) or OR(95% CI)* P
Birth outcomes
 GA at birth, wk 39.3 (1.4) 39.1 (1.3) −0.2 (−1.7 to 1.3) 0.78
 Infant birth weight, g 3047 (455) 3263 (360) 216.9 (−230.4 to 664.0) 0.32
 Head circumference at birth, cm 33.1 (1.7) 33.5 (1.7) 0.4 (−1.4 to 2.2) 0.62
 Apgar score at 1 min 8.1 (0.8) 8.5 (0.6) 0.4 (−0.3 to 1.2) 0.24
 Apgar score at 5 min 8.8 (0.4) 9.2 (0.4) 0.4 (0–0.9) 0.08
 Congenital anomaly 0 1 (17%)† Not calculated 0.32
 Breastfeeding initiated 8 (62%) 5 (83%) 3.1 (0.2–176.8) 0.70
 NICU admission 1 (8%) 0 Not calculated 0.99
 Discharged in nonparental custody 0 1 (17%) Not calculated 0.32
NAS outcomes
 NAS diagnosis 12 (92%) 0 Not calculated <0.001
 Pharmacologic treatment for NAS 6 (46%) 0 Not calculated 0.11
 Length of hospital stay, d 10.9 (8.2) 3.2 (1.6) −7.8 (−13.0 to −2.5) 0.008

GA = gestational age; MD = mean difference; NAS = neonatal abstinence syndrome; NICU = neonatal intensive care unit.

*

Odds ratio (OR) for naltrexone versus buprenorphine.

†

Mild unilateral renal pyelectasis.